nach oben

best practice onkologie

Erschienen in:

02.12.2015 | CME_Topic

Akute myeloische Leukämie

verfasst von: PD Dr. med. Peter Staib, Stephanie Lippl, Karsten Spiekermann

Erschienen in: best practice onkologie | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die akute myeloische Leukämie (AML), eine maligne Erkrankung der hämatopoetischen Stammzelle, ist charakterisiert durch Proliferation und Akkumulation unreifer myeloischer Zellen. Die Diagnose wird anhand des Differenzialblutbilds und des Knochenmarks gestellt und umfasst neben der initialen Zytomorphologie die Immunphänotypisierung sowie Molekular- und Zytogenetik. Durch moderne Chemotherapie-Regime kann bei etwa 70–80% der erwachsenen AML-Patienten (18–60 Jahre) eine Komplettremission (CR) erreicht werden und bei etwa 25–35% ein leukämiefreies Langzeitüberleben. Aufgrund fortschreitender Erkenntnisse zu den molekularen Grundlagen der AML werden zunehmend zielgerichtete Therapieoptionen entwickelt, die jedoch noch keinen Eingang in die klinische Routine in der Behandlung der AML gefunden haben.

Aurelius J, Martner A, Brune M et al (2012) Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells. Haematologica 97:1904–1908PubMedCentralCrossRefPubMed

Braess J, Kreuzer K-A, Spiekermann K et al (2013) High efficacy and significantly shortened neutropenia of dose-dense S-HAM as compared to standard double induction: first results of a prospective randomized trial (AML-CG 2008). Blood 122:619–619CrossRef

Braess J, Spiekermann K, Staib P et al (2009) Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood 113:3903–3910CrossRefPubMed

Brune M, Castaigne S, Catalano J et al (2006) Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 108:88–96CrossRefPubMed

Büchner T, Berdel WE, Schoch C et al (2006) Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 24:2480–2489CrossRefPubMed

Büchner T, Hiddemann W, Berdel WE et al (2003) 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 21:4496–4504CrossRefPubMed

Büchner T, Urbanitz D, Hiddemann W et al (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3:1583–1589PubMed

Burnett A, Wetzler M, Lowenberg B (2011) Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29:487–494CrossRefPubMed

Burnett AK, Milligan D, Prentice AG et al (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109:1114–1124CrossRefPubMed

10.

Byrd JC, Dodge RK, Carroll A et al (1999) Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 17:3767–3775PubMed

11.

Byrd JC, Mrozek K, Dodge RK et al (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325–4336CrossRefPubMed

12.

Cheson BD, Bennett JM, Kopecky KJ et al (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642–4649CrossRefPubMed

13.

Cornelissen JJ, Breems D, Van Putten WL et al (2012) Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol 30:2140–2146CrossRefPubMed

14.

Döhner H, Estey EH, Amadori S et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453–474CrossRefPubMed

15.

Dombret H, Seymour JF, Butrym A et al (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126:291–299PubMedCentralCrossRefPubMed

16.

Estey E, Dohner H (2006) Acute myeloid leukaemia. Lancet 368:1894–1907CrossRefPubMed

17.

Fernandez HF, Sun Z, Yao X et al (2009) Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361:1249–1259PubMedCentralCrossRefPubMed

18.

Fischer T, Stone RM, Deangelo DJ et al (2010) Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 28:4339–4345PubMedCentralCrossRefPubMed

19.

Grimwade D, Walker H, Oliver F et al (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 92:2322–2333PubMed

20.

Juliusson G, Antunovic P, Derolf A et al (2009) Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113:4179–4187CrossRefPubMed

21.

Kantarjian HM, Thomas XG, Dmoszynska A et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670–2677CrossRefPubMed

22.

Koreth J, Schlenk R, Kopecky KJ et al (2009) Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 301:2349–2361PubMedCentralCrossRefPubMed

23.

Krug U, Röllig C, Koschmieder A et al (2010) Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 376:2000–2008CrossRefPubMed

24.

Lee JH, Joo YD, Kim H et al (2011) A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 118:3832–3841CrossRefPubMed

25.

Lengfelder E, Haferlach C, Saussele S et al (2009) High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia 23:2248–2258CrossRefPubMed

26.

Lo-Coco F, Avvisati G, Vignetti M et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369:111–121CrossRefPubMed

27.

Löwenberg B (2013) Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 121:26–28CrossRefPubMed

28.

Löwenberg B, Ossenkoppele GJ, Van Putten W et al (2009) High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361:1235–1248CrossRefPubMed

29.

Löwenberg B, Pabst T, Vellenga E et al (2011) Cytarabine dose for acute myeloid leukemia. N Engl J Med 364:1027–1036CrossRefPubMed

30.

Mrozek K, Marcucci G, Nicolet D et al (2012) Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol 30:4515–4523PubMedCentralCrossRefPubMed

31.

NCCN-Guidelines. (2015) Acute myeloid leukemia. Version 1.2015. In

32.

Ohtake S, Miyawaki S, Fujita H et al (2011) Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 117:2358–2365CrossRefPubMed

33.

Röllig C, Bornhauser M, Thiede C et al (2011) Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol 29:2758–2765CrossRefPubMed

34.

Sanz MA, Grimwade D, Tallman MS et al (2009) Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113:1875–1891CrossRefPubMed

35.

Sanz MA, Montesinos P, Rayon C et al (2010) Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 115:5137–5146CrossRefPubMed

36.

Schlenk RF, Dohner K, Krauter J et al (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909–1918CrossRefPubMed

37.

Sorror ML, Storb RF, Sandmaier BM et al (2014) Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol 32:3249–3256PubMedCentralCrossRefPubMed

38.

Stein EM, Altman JK, Collins R et al (2014) AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a phase I study in patients with IDH2 mutation positive advanced hematologic malignancies. Blood 124:115–115

39.

Stelljes M, Beelen DW, Braess J et al (2011) Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial. Haematologica 96:972–979PubMedCentralCrossRefPubMed

40.

Swerdlow SH; Campo E, Harris NL, Jaffe ES et al (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Lyon

41.

Tefferi A, Letendre L (2012) Going beyond 7 + 3 regimens in the treatment of adult acute myeloid leukemia. J Clin Oncol 30:2425–2428CrossRefPubMed

42.

Willemze R, Suciu S, Meloni G et al (2014) High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol 32:219–228CrossRefPubMed

Titel: Akute myeloische Leukämie
verfasst von: PD Dr. med. Peter Staib
Stephanie Lippl
Karsten Spiekermann
Publikationsdatum: 02.12.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: best practice onkologie / Ausgabe 6/2015
Print ISSN: 0946-4565
Elektronische ISSN: 1862-8559
DOI: https://doi.org/10.1007/s11654-015-0247-9

Springer Medizin

Akute myeloische Leukämie

Zusammenfassung

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2015

Sterbehilfegesetz: Die ethische Verantwortung bleibt

Aspirin und gastrointestinale Karzinome

Tumoren des oberen Gastrointestinaltraktes

Interne Kommunikation

Patientenzentrierte Kommunikation

Doch Krebsrisiko durch Brustimplantate?

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie